Peptides DB

Research-centric peptide and protocol reference hub

AOD-9604 vs Tesamorelin

Updated July 23, 2026 · Reviewed by the PeptidesDB Editorial team

AOD-9604: Research use — not FDA-approvedTesamorelin: FDA-approved

A data-driven comparison of AOD-9604 and Tesamorelin (also searched as Tesamorelin vs AOD-9604) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

AOD-9604 centers on metabolic, while Tesamorelin leans toward metabolic. On indexed research, Tesamorelin is ahead (AOD-9604: 4 studies, Human evidence; Tesamorelin: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • AOD-9604 is strongest for metabolic; Tesamorelin for metabolic.
  • Evidence: AOD-9604 Human evidence (4 studies) vs Tesamorelin Human clinical (5).
  • Check the FDA-approval status chips above before assuming a legal use pathway.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
AOD-9604Tesamorelin

At a glance

AOD-9604Human evidence

Modified hGH Fragment | Fat Loss Peptide

Strongest: MetabolicStudies: 4Level: Well Studied
TesamorelinHuman clinical

GHRH Analog | Visceral Fat Reduction

Strongest: MetabolicStudies: 5Level: FDA Approved

AOD-9604 vs Tesamorelin: side-by-side

MetricAOD-9604Tesamorelin
ClassWeight LossGH
Regulatory statusResearch use onlyFDA-approved
Evidence gradeHuman evidenceHuman clinical
Studies indexed45
Research levelWell StudiedFDA Approved
Strongest effectMetabolic & appetiteMetabolic & appetite
Healing & recovery2.01.0
Muscle & body comp3.02.0
Metabolic & appetite4.04.0
Neuro & mood0.01.0
Sleep & circadian0.00.0
Inflammation & immune2.01.0
Skin & aesthetics3.03.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyAOD-9604Tesamorelin
MechanismModified hGH fragment (176–191)GHRH analog
RouteSubcutaneous injection (research use)Subcutaneous injection
Half-life~26–38 min

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is AOD-9604?

A GH-fragment–derived peptide primarily discussed for fat loss and body-composition change, sometimes with cartilage and joint-repair context.

Full AOD-9604 profile, mechanism & studies →

What is Tesamorelin?

### Tesamorelin Summary Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog, primarily investigated for its potential to reduce visceral fat in individuals with HIV-associated lipodystrophy. Its role in metabolic health and body composition continues to be explored in various clinical contexts.

Full Tesamorelin profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingAOD-96042.0/5 effect signal
MuscleAOD-96043.0/5 effect signal
MetabolicEvenBoth ~4.0/5
NeuroTesamorelin1.0/5 effect signal
InflammationAOD-96042.0/5 effect signal
SkinEvenBoth ~3.0/5

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack AOD-9604 and Tesamorelin?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

AOD-9604 vs Tesamorelin: side effects

AOD-9604

No community-reported effects logged yet.

Tesamorelin

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

AOD-9604 has 4 approved studies indexed (Human evidence), and Tesamorelin has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is AOD-9604 or Tesamorelin better?

It depends on your goal. AOD-9604 is strongest for metabolic; Tesamorelin for metabolic. Tesamorelin has more indexed studies (5). See the goal-by-goal breakdown above.

Is AOD-9604 or Tesamorelin better for weight loss?

They score similarly on the metabolic/appetite axis in the community data.

Is AOD-9604 or Tesamorelin better for muscle?

AOD-9604 leads on the muscle & body-composition axis (3.0/5).

Which has more research, AOD-9604 or Tesamorelin?

AOD-9604 has 4 approved studies indexed (Human evidence); Tesamorelin has 5 (Human clinical). Higher counts mean more to read, not proven superiority.

Can you stack AOD-9604 and Tesamorelin?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of AOD-9604 vs Tesamorelin?

AOD-9604: no community-reported effects logged yet. Tesamorelin: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is AOD-9604 or Tesamorelin FDA-approved?

AOD-9604 is a research-use compound and is not FDA-approved. Tesamorelin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Tesamorelin better than AOD-9604?

For metabolic, Tesamorelin has the edge; for metabolic, AOD-9604 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 23, 2026.